Giovanni Francesco Pellicanò

21PUBLICATIONS
73CO-AUTHORS
Behavioural epidemiologyPharmaceutical delivery technologiesCancer cell biologyFeminist theoryCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 23, 2026
Virologic, Lipid, Renal and Hepatic Laboratory Outcomes After Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Experienced People with HIV: Real-World Evidence from the SHINe-SHIC Cohort.

|Nov 27, 2025
Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study.

Giuseppe Nicolò Conti, Serena Spampinato, Andrea De Vito

|Aug 28, 2025
Investigating the Impact of Fusobacterium nucleatum on Oxidative Stress, Chemoresistance, and Inflammation in Inflammatory Bowel Disease and Colorectal Cancer: Rationale and Design of a Clinical Trial.

Pierluigi Consolo, Carlotta Giorgi, Concetta Crisafulli

|Jul 30, 2025
CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation.

Serena Spampinato, Emmanuele Venanzi Rullo, Giuseppe Nicolò Conti

|Mar 26, 2025
The Challenging Scenario of Cancer Treatment for People with HIV: Clinical Experience with Immune Checkpoint Inhibitors.

Tindara Franchina, Patrizia Carroccio, Ylenia Russotto

|Oct 26, 2024
Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort.

Agnese Colpani, Andrea De Vito, Andrea Marino

Pageof 4

Frequent Collaborators

12 joint publications

Benedetto Maurizio Celesia

9 joint publications

Giuseppe Nunnari

8 joint publications

Emmanuele Venanzi Rullo

7 joint publications

Andrea Marino